Log in

Relevant bibliographies by topics / Cycle de consolidation / Journal articles

To see the other types of publications on this topic, follow the link: Cycle de consolidation.

Journal articles on the topic 'Cycle de consolidation'

Author: Grafiati

Published: 4 June 2021

Last updated: 12 April 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Cycle de consolidation.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Marvin-Peek, Jennifer, Courtney D. DiNardo, Wei-Ying Jen, et al. "Less May be More: The Impact of Post-Remission Intensive (IC) Consolidation Cycles on Outcomes in Newly Diagnosed Acute Myeloid Leukemia Receiving IC + Venetoclax." Blood 144, Supplement 1 (2024): 1472. https://doi.org/10.1182/blood-2024-202405.

Full text

Abstract:

Background: Intensive induction and consolidation chemotherapy (IC) is the standard of care for fit patients (pts) with newly diagnosed acute myeloid leukemia (AML). The addition of venetoclax (VEN) to IC regimens such as cladribine, idarubicin, and cytarabine (CLIA) and fludarabine, cytarabine, idarubicin, and filgrastim (FLAG-IDA) has shown excellent outcomes in clinical trials. However, these IC regimens and subsequent consolidation cycles can be associated with additional risks, including myelosuppression and febrile neutropenia. The optimal number of IC cycles to maximize long-term outcom

APA, Harvard, Vancouver, ISO, and other styles

2

Revlina, Intan, Indah Lestari, and Sumarwiyah Sumarwiyah. "Peningkatan Kematangan Pilihan Karir Peserta Didik Melalui Layanan Informasi Bermuatan Internet." Jurnal Muria Research Guidance and Counseling (MRGC) 2, no. 2 (2023): 120–26. http://dx.doi.org/10.24176/mrgc.v2i2.10532.

Full text

Abstract:

The purpose of this study are: 1) to describe the implementation of Internet-based information services in an effort to increase the consolidation of students' career choices. 2) Obtaining Increased Consolidation of Student Career Choices through Internet-Based Information ServicesThe results of research on Strengthening Career Choices Students in the Pre-Cycle obtained a score of 14 (47%) in the Poor category, in Cycle I obtained an average score of 20 (67%) in the Enough category and in Cycle II obtained an average score of 2 (87%) in the Very Good category.The conclusions of this study are:

APA, Harvard, Vancouver, ISO, and other styles

3

Zhang, Dongliang, Guangqing Yang, Xiaodi Niu, Lu Zhang, and Zhijie Wang. "Study on Application Effect of Sand Consolidating Agent for the Slope of Highway Subgrade in Season Frozen Zone." Advances in Civil Engineering 2019 (November 21, 2019): 1–7. http://dx.doi.org/10.1155/2019/3716153.

Full text

Abstract:

In deep season frozen areas, the solidified layer is easy to be destroyed due to the influence of freeze-thaw cycles after the surface layer of the sandy slope is solidified by chemical methods. In order to study the application effect of the new sand consolidating agent after solidifying sand body, the mechanism of strength formation was analyzed by scanning electron microscopy (SEM). The freeze-thaw cycle tests were carried out on sand consolidating samples. The direct shear tests and unconfined compressive strength tests were carried out before and after freeze-thaw cycles to analyze the fr

APA, Harvard, Vancouver, ISO, and other styles

4

Bejanyan, Nelli, Aleksandr Lazaryan, Mei-Jie Zhang, et al. "Consolidation Chemotherapy Is Not Beneficial for Adult Acute Lymphoblastic Leukemia Patients with Available Donor Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation in First Complete Remission: A CIBMTR Study." Blood 128, no. 22 (2016): 684. http://dx.doi.org/10.1182/blood.v128.22.684.684.

Full text

Abstract:

Abstract Allogeneic hematopoietic cell transplantation (alloHCT) is potentially curative for patients with ALL who achieve complete remission with upfront chemotherapy (CR1). However, the necessity of consolidation chemotherapy remains uncertain in patients with an available donor undergoing alloHCT, even if the goal is to reduce the detectable disease burden prior to alloHCT. We therefore compared clinical outcomes of 524 adult patients with ALL in CR1 who received ≥2 cycles (n=109) vs. 1 cycle (n=93) vs. no (n=322) consolidation chemotherapy prior to myeloabalative alloHCT from 2008-2012. Th

APA, Harvard, Vancouver, ISO, and other styles

5

Saini, Lalit, Mark D. Minden, Andre Schuh, et al. "An Evaluation of Septicemia During Outpatient Consolidation Chemotherapy for Acute Myeloid Leukemia." Blood 118, no. 21 (2011): 4268. http://dx.doi.org/10.1182/blood.v118.21.4268.4268.

Full text

Abstract:

Abstract Abstract 4268 Introduction: Ambulatory chemotherapy for acute myeloid leukemia (AML) is believed to reduce exposure to nosocomial multi-drug resistant organisms and the incidence of septicemia. Materials and Methods: In this retrospective analysis we assessed the frequency of septicemia in patients receiving consolidation therapy: 256 patients received the first consolidation cycle (C1) and 217 the second consolidation cycle (C2). Patients received consolidation as inpatients or on an ambulatory basis. All ambulatory patients received infection prophylaxis with ciprofloxacin, amoxicil

APA, Harvard, Vancouver, ISO, and other styles

6

Batchelor, Tracy, Sharmila Giri, Amy S. Ruppert, et al. "Myeloablative versus non-myeloablative consolidative chemotherapy for newly diagnosed primary central nervous system lymphoma: Results of induction therapy in Alliance 51101." Journal of Clinical Oncology 38, no. 15_suppl (2020): 8042. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.8042.

Full text

Abstract:

8042 Background: Optimal consolidative therapy for primary central nervous system lymphoma (PCNSL) is not defined. Avoidance of whole brain radiation may reduce risk of neurotoxicity. Non-radiation consolidative options include myeloablative chemotherapy followed by autologous stem cell transplantation (HDT/ASCT) or non-myeloablative chemotherapy. Methods: This is a randomized phase 2, National Clinical Trials Network study of induction methotrexate (MTX) (8 g/m2days 1, 15), temozolomide (TMZ) (150-200 mg/m2 D7-11), and rituximab (RTX) (C1 D3, 10, 17, 24 and C2 D3, 10) in four 28-day cycles fo

APA, Harvard, Vancouver, ISO, and other styles

7

Wei, Andrew, Gail J. Roboz, Hervé Dombret, et al. "CC-486 Improves Overall Survival (OS) and Relapse-Free Survival (RFS) for Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC), Regardless of Amount of Consolidation Received: Results from the Phase III QUAZAR AML-001 Maintenance Trial." Blood 136, Supplement 1 (2020): 38–40. http://dx.doi.org/10.1182/blood-2020-138498.

Full text

Abstract:

Background: Approximately 40-60% of older patients (pts) with AML achieve complete remission (CR) with IC. Factors influencing the use of consolidation after induction include disease-related considerations, extent of hematopoietic recovery, pt fitness, and physician and pt preference. Most older pts who achieve AML remission will experience disease relapse despite consolidation therapy (Schlenk, Haematologica, 2018). In the phase III, randomized, double-blind QUAZAR AML-001 Maintenance Trial, CC-486, an oral hypomethylating agent, was shown to significantly prolong OS and RFS vs. placebo (PBO

APA, Harvard, Vancouver, ISO, and other styles

8

Sperr, Wolfgang R., Susanne Herndlhofer, Karoline V. Gleixner, et al. "Intensive Post-Remission Consolidation with G-CSF-Support: Tolerability, Safety, Reduced Hospitalization, and Efficacy of a New Treatment Protocol for AML Patients ≥60 Years." Blood 128, no. 22 (2016): 2797. http://dx.doi.org/10.1182/blood.v128.22.2797.2797.

Full text

Abstract:

Abstract Treatment of AML in elderly patients (≥60 years) deserves special considerations and has to balance toxicity against efficacy as well as life expectancy against the risk of AML-related death and relapse after intensive treatment. We have previously shown that induction chemotherapy followed by repetitive cycles of intermediate dose ARA-C (IDAC) is a well-tolerated and highly effective approach for elderly patients with AML (Sperr et al, Clin Cancer Res 2004;10:3965-3971). The aim of the current multi-center study (EudraCT number: 2007-005806-29) was to evaluate the efficacy and feasib

APA, Harvard, Vancouver, ISO, and other styles

9

Marvin-Peek, Jennifer, Hagop M. Kantarjian, Wei-Ying Jen, et al. "Impact of Post-Remission Intensive (IC) Consolidation Chemotherapy Cycles on Overall and Relapse Free Survival after Allogeneic Stem Cell Transplant (SCT) in Patients with Acute Myeloid Leukemia (AML) Receiving IC + Venetoclax." Blood 144, Supplement 1 (2024): 3572. https://doi.org/10.1182/blood-2024-202414.

Full text

Abstract:

Background: Allogeneic stem cell transplantation (SCT) is recommended for younger or fit patients with acute myeloid leukemia (AML) in first complete remission (CR1) who possess a relapse risk exceeding 35-40% (Dohner et al., 2022). The ideal number of post-remission intensive consolidation chemotherapy (IC) cycles prior to allogeneic SCT is currently unknown. With the addition of venetoclax (VEN) to high intensity regimens such as cladribine, idarubicin, and cytarabine (CLIA) and fludarabine, cytarabine, idarubicin, and filgrastim (FLAG-IDA), we sought to determine if patients who had receive

APA, Harvard, Vancouver, ISO, and other styles

10

Lodge, David, and Marta Rodriguez-Vives. "How long can austerity persist? The factors that sustain fiscal consolidations." European Journal of Government and Economics 2, no. 1 (2013): 5. http://dx.doi.org/10.17979/ejge.2013.2.1.4284.

Full text

Abstract:

To put public debt on a sustainable path, many governments face the task of enacting large fiscal consolidation followed by years of sustained primary surpluses. By estimating hazard functions for the duration of consolidations, we analyse the features of past consolidation efforts across a panel of advanced economies. Our contribution is to identify the factors that help to start and sustain consolidations, separately discussing governments’ “commitment” to the cause as well as their “capacity” for action. Our analysis suggests that longer consolidations are initiated when public debt is high

APA, Harvard, Vancouver, ISO, and other styles

11

Vale, Colin, Dimitrios Farmakiotis, Pamela C. Egan, Randall Ingham, and John L. Reagan. "Outcomes Associated with Antimicrobial Use during High Dose Cytarabine Consolidation in Acute Myeloid Leukemia." Blood 132, Supplement 1 (2018): 1402. http://dx.doi.org/10.1182/blood-2018-99-110175.

Full text

Abstract:

Abstract Introduction: Patients with acute myeloid leukemia (AML) undergoing consolidation chemotherapy with high dose cytarabine (HiDAC) are often placed on prophylactic antimicrobials. This practice is largely based on the defined benefit of antimicrobial prophylaxis for AML patients during induction chemotherapy. Recent concerns regarding antimicrobial prophylaxis include increased risk of Clostridium difficile colitis, antimicrobial toxicities, and the potential for fostering multidrug-resistant pathogens. These emerging concerns coupled with the relatively shorter duration of neutropenia

APA, Harvard, Vancouver, ISO, and other styles

12

Zang, Meng, Jun Tai, and Haijun Lu. "Microstructure and Mechanical Properties of Expansive Clay under Drying–Wetting Cycle." Applied Sciences 13, no. 13 (2023): 7464. http://dx.doi.org/10.3390/app13137464.

Full text

Abstract:

Expansive clay is one of the most widely distributed soils in the world. Due to its rich content of strongly hydrophilic minerals—such as montmorillonite—expansive clay exhibits substantial swelling and shrinkage properties, and overconsolidation. The formation process of undisturbed expansive clay has a long and complicated geological history and innumerable drying–wetting cycles, resulting in the formation of special internal structures. In this study, the mud-to-natural-consolidation deposition process was simulated using a saturated mud-remolded sample preparation device, and then, mud-rem

APA, Harvard, Vancouver, ISO, and other styles

13

Batchelor, Tracy, Sharmila Giri, Amy S. Ruppert, et al. "Myeloablative versus non-myeloablative consolidative chemotherapy for newly diagnosed primary central nervous system lymphoma: Results of CALGB 51101 (Alliance)." Journal of Clinical Oncology 39, no. 15_suppl (2021): 7506. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.7506.

Full text

Abstract:

7506 Background: Optimal consolidative therapy for primary central nervous system lymphoma (PCNSL) is not defined. Avoidance of whole brain radiation may reduce risk of neurotoxicity. Non-radiation consolidative options include myeloablative chemotherapy with autologous stem cell transplantation (HDT/ASCT) or non-myeloablative chemotherapy. Methods: This is a randomized phase 2, National Clinical Trials Network study of induction methotrexate (MTX) (8 g/m2 days 1, 15), temozolomide (TMZ) (150-200 mg/m2 D7-11), and rituximab (RTX) (C1 D3, 10, 17, 24 and C2 D3, 10 ) in four 28-day cycles followe

APA, Harvard, Vancouver, ISO, and other styles

14

Viiala, Nicholas, Omali Pitiyarachchi, Heather Range, et al. "Impact of Outpatient Administration of Cytarabine Consolidation Chemotherapy on Hospital Length of Stay in Adults with Acute Myeloid Leukemia." Blood 142, Supplement 1 (2023): 3723. http://dx.doi.org/10.1182/blood-2023-187963.

Full text

Abstract:

Background: Administration of 3-4 cycles of high/intermediate dose cytarabine (H/IDAC) reduces relapse of acute myeloid leukemia (AML) and bridges patients (pts) to allograft. There is no accepted standard model of safely delivering H/IDAC in these pts. To reduce reliance on inpatient (inpt) chemotherapy administration and safely avoid or forestall hospitalization during cycles, we developed an outpatient (outpt) protocol to deliver H/IDAC. Pts were assigned outpt or inpt treatment at their hematologist's discretion. We aimed to evaluate the benefits and safety of our model in this retrospecti

APA, Harvard, Vancouver, ISO, and other styles

15

Markman, M. "Consolidation therapy revisited: intravenous chemotherapy." International Journal of Gynecologic Cancer 13, Suppl 2 (2003): 204–7. http://dx.doi.org/10.1136/ijgc-00009577-200311001-00013.

Full text

Abstract:

The administration of ‘consolidation’ therapy is designed to maximize the benefits achieved from primary chemotherapy, to both improve progression-free and overall survival. Paclitaxel is an excellent agent to consider for a consolidation strategy in ovarian cancer, based on its activity in the disease, its cycle-specificity, and the lack of serious cumulative toxicity (except for neuropathy). A recently reported randomized trial conducted by the South-west Oncology Group and the Gynecologic Oncology Group revealed that 12-monthly cycles of single-agent paclitaxel (175 mg/m2 over 3 h) improves

APA, Harvard, Vancouver, ISO, and other styles

16

Niederwieser, Dietger, Rainer Krahl, Christian Jakob, et al. "Increasing The Dose Of AraC In Consolidation Therapy Does Not Lead To Higher Overall Survival Or Improved Relapse Incidence In Patients With AML Over The Age Of 60 Years." Blood 122, no. 21 (2013): 2645. http://dx.doi.org/10.1182/blood.v122.21.2645.2645.

Full text

Abstract:

Abstract The optimal consolidation chemotherapy in AML patients >60 years has yet to be defined in detail. Although age-adjusted induction chemotherapy results in CR rates comparable to those in younger patients, relapse remains the major hurdle to successful treatment. While the role of stem cell transplantation (HSCT) in elderly patients is currently being evaluated in randomized studies, we focus here on the intensity of consolidation chemotherapy. Patients data from the elderly AML trials OSHO 1997 (n=410) and OSHO 2004 (n=733) were pooled and analyzed. These protocols have identical in

APA, Harvard, Vancouver, ISO, and other styles

17

Pan, Jiajia, Huafeng Wang, Liping Mao, et al. "Venetoclax Plus ‘2 + 5‘ Modified Intensive Chemotherapy with Daunorubicin and Cytarabine in Fit Elderly Patients with Untreated De Novo Acute Myeloid Leukaemia: A Single-Centre Retrospective Analysis." Blood 142, Supplement 1 (2023): 2912. http://dx.doi.org/10.1182/blood-2023-180770.

Full text

Abstract:

Background: The treatment options for elderly patients with acute myeloid leukemia (AML) have been limited considering the poor tolerability of intensive standard chemotherapy. Recently, we report promising clinical outcomes in 13 untreated fit elderly patients with AML who received modified intensive induction of venetoclax in combination with ‘2 + 5‘ (daunorubicin and cytarabine) chemotherapy (modified DAV regimen), followed by venetoclax plus modified intermediate-dose cytarabine consolidation. Building on this foundation, we expanded the sample size and included 11 more patients who treate

APA, Harvard, Vancouver, ISO, and other styles

18

Park, Steven I., Lakshmi Nayak, Danielle Boselli, et al. "High-Dose Methotrexate Containing Induction Chemotherapy Followed By Nivolumab Consolidation in Older (≥ 65) Patients with Previously Untreated Primary CNS Lymphoma." Blood 142, Supplement 1 (2023): 1723. http://dx.doi.org/10.1182/blood-2023-179526.

Full text

Abstract:

Introduction: High-dose methotrexate (HD-MTX)-containing chemotherapy followed by either autologous stem cell transplant (ASCT) or whole-brain irradiation (WBI) is widely considered the standard for primary CNS lymphoma (PCNSL) treatment. However, many older frail patients with PCNSL are unable to undergo ASCT or WBI due to increased risk of treatment-related toxicity, such as infections and neurotoxicity. Without consolidation, survival outcomes are significantly worse, with a 3-year progression free survival (PFS) rate of ~ 30%. Therefore, novel therapeutic approaches are urgently needed for

APA, Harvard, Vancouver, ISO, and other styles

19

West, Tracey. "Equity Holdings of Australian Baby Boomers-Comparing Life Cycle Phases." Financial Planning Research Journal 3, no. 2 (2017): 87–109. http://dx.doi.org/10.2478/fprj-2017-0010.

Full text

Abstract:

ABSTRACT This study aims to quantify the role of equity holdings in the asset portfolios of baby boomers over the accumulation and consolidation life cycle phases, and characteristics of baby boomer households that hold equities. The results did not confirm the hypothesis that baby boomer households have increased direct equity ownership in the consolidation phase and it is likely that the global financial crisis (GFC) reduced baby boomer household investment in equities. It may be of comfort to policy makers that baby boomer households are not at peak levels of equity market volatility exposu

APA, Harvard, Vancouver, ISO, and other styles

20

Luger, Selina M., Zhuoxin Sun, Ryan J. Mattison, et al. "Assessment of Outcomes of Consolidation Therapy By Number of Cycles of Blinatumomab Received in Newly Diagnosed Measurable Residual Disease Negative Patients with B-Lineage Acute Lymphoblastic Leukemia: In the ECOG-ACRIN E1910 Randomized Phase III National Clinical Trials Network Trial." Blood 142, Supplement 1 (2023): 2877. http://dx.doi.org/10.1182/blood-2023-189648.

Full text

Abstract:

Introduction: ECOG ACRIN E1910 is a randomized phase III trial that showed that adults with newly diagnosed BCR::ABL1 negative acute lymphoblastic leukemia (ALL) who become MRD negative (&lt;0.01%) after induction chemo who receive blinatumomab with conventional chemotherapy (chemo) have improved survival compared with those who received chemo only (Litzow et al, Blood (2022) 140: Supplement 2, LBA-1). However, not all pts were able to receive all four planned cycles of blinatumomab in consolidation. In this report we assessed outcomes of pts in the blinatumomab arm of the trial who receiv

APA, Harvard, Vancouver, ISO, and other styles

21

Arora, Arshia, Hua-Ling Tsai, Venkata Preetam Sandeep Kaduluri, Mark J. Levis, and Alexander J. Ambinder. "A Retrospective Cohort Analysis of Minimal Residual Disease (MRD) across Therapy in FLT3 Acute Myeloid Leukemia (AML)." Blood 144, Supplement 1 (2024): 6171. https://doi.org/10.1182/blood-2024-211081.

Full text

Abstract:

BACKGROUND FLT3-ITD measurable residual disease (MRD), as assessed by next generation sequencing (NGS), is increasingly used as a prognostic and predictive marker. Patients with FLT3-ITD mutated AML who are in remission have a higher risk of relapse and reduced overall survival if they have detectable FLT3-ITD MRD,1 even in the immediate pre-transplant setting.2 The use of post-transplant gilteritinib maintenance in patients with pre-transplant FLT3-ITD MRD largely mitigates the negative impact of FLT3-ITD MRD on relapse-free survival. FLT3-ITD MRD may therefore be a useful surrogate marker fo

APA, Harvard, Vancouver, ISO, and other styles

22

Allan, John N., Daniel Helbig, Erin Mulvey, et al. "Zanubrutinib and Venetoclax As Initial Therapy for CLL/SLL with Obinutuzumab Triplet Consolidation in Patients with Minimal Residual Disease Positivity (BruVenG)." Blood 142, Supplement 1 (2023): 3285. http://dx.doi.org/10.1182/blood-2023-174465.

Full text

Abstract:

Background: Bruton's tyrosine kinase inhibitors (BTKi), anti-CD20 antibodies, and B cell lymphoma 2 inhibitors (BCL-2i) are essential therapeutic drug classes in the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Clinical synergy of BTKi and BCL-2i combinations have been observed, which allow for an oral regimen, that can be safely administered in a clinic setting for most patients (Tam et al., 2022; Wierda et al., 2021). Still, it remains uncertain if anti-CD20 antibodies meaningfully add to the effectiveness of oral combination therapy. Recent reports of trip

APA, Harvard, Vancouver, ISO, and other styles

23

Fenk, Roland, Julia Baier, Aristoteles Giagounidis, et al. "Safety and Efficacy of a Six Month Full Dose Lenalidomide Consolidation Treatment After First-Line High-Dose Therapy in Patients with Multiple Myeloma." Blood 120, no. 21 (2012): 1982. http://dx.doi.org/10.1182/blood.v120.21.1982.1982.

Full text

Abstract:

Abstract Abstract 1982 Background: Consolidation with 2 cycles of 25 mg lenalidomide and/or maintenance treatment with a dosage of 10–15 mg lenalidomide after high-dose therapy (HDT) and autologous stem cell transplantation (SCT) improves event-free survival (EFS) in patients with multiple myeloma (MM), as has been shown recently by two randomised clinical trials in the US and France with patients up to the age of 70 and 65, respectively. So far data on longer consolidation treatment and different dosages in the maintenance setting is lacking. Methods: In the randomized, open label phase III L

APA, Harvard, Vancouver, ISO, and other styles

24

Boyiadzis, Michael M., Marcos J. G. de Lima, Mei-Jie Zhang, et al. "Prompt CR Plus Consolidation Therapy Yields Improve Survival after Allogeneic Transplantation for AML Patients Receiving Myeloablative, but Not Reduced-Intensity Conditioning: A CIBMTR Analysis." Blood 138, Supplement 1 (2021): 414. http://dx.doi.org/10.1182/blood-2021-149962.

Full text

Abstract:

Abstract Leukemia relapse and treatment related mortality (TRM) remain major obstacles for successful allogeneic hematopoietic cell transplantation (allo-HCT). The number of induction cycles using intensive chemotherapy at AML diagnosis to achieve complete remission (CR) and the number of consolidation cycles and disease status at the time of allo-HCT for patients with acute myeloid leukemia (AML) may each affect TRM and relapse rates. We investigated the impact of the number of induction/consolidation cycles and disease status on the success of allo-HCT in 3113 AML patients reported to the Ce

APA, Harvard, Vancouver, ISO, and other styles

25

Moreau, Philippe, Cyrille Hulin, Denis Caillot, et al. "Ixazomib-Lenalidomide-Dexamethasone (IRd) Combination before and after Autologous Stem Cell Transplantation (ASCT) Followed By Ixazomib Maintenance in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Phase 2 Study from the Intergroupe Francophone Du MyéLome (IFM)." Blood 128, no. 22 (2016): 674. http://dx.doi.org/10.1182/blood.v128.22.674.674.

Full text

Abstract:

Abstract Background Frontline ASCT is the standard of care for patients with symptomatic NDMM less than 66 years of age. 3-drug combinations are the standard induction regimens prior to ASCT. Consolidation therapy after ASCT is aimed at improving disease control through deepening responses. Maintenance therapy is administered with the objective of prolonging response duration. The all-oral combination of weekly ixazomib plus lenalidomide and dexamethasone (IRd) was recently evaluated in NDMM, was generally well tolerated and appeared active (Kumar et al, Lancet Oncology 2014;13:1503-12). We an

APA, Harvard, Vancouver, ISO, and other styles

26

Du, Steven, Uvin Ko, Daniela Bota, and Xiao-Tang Kong. "INNV-28. POTENTIAL EFFECTIVE CONSOLIDATION THERAPY WITH SINGLE AGENT IBRUTINIB FOR A CASE WITH PRIMARY CNS LYMPHOMA AFTER INITIAL HD-MTX AND RITUXIMAB INDUCTION THERAPY." Neuro-Oncology 23, Supplement_6 (2021): vi111. http://dx.doi.org/10.1093/neuonc/noab196.439.

Full text

Abstract:

Abstract INTRODUCTION Primary CNS Lymphoma (PCNSL) is a rare and aggressive cancer that originates from lymphocytes and develops in the central nervous system. Standard induction therapy involves high-dose methotrexate (HD-MTX)-based chemotherapy, which achieves complete or partial response in most PCNSL patients. However, there is no standard consolidation therapy. We report one case in which ibrutinib, a Bruton’s tyrosine kinase inhibitor, replaced low-dose WBRT as consolidation therapy after induction by HD-MTX and rituximab. Ibrutinib treatment yielded good tolerance and further resolution

APA, Harvard, Vancouver, ISO, and other styles

27

Thakkar, Jigisha, Michael Teitcher, Douglas Anderson, Kevin Barton, and Edward Melain. "COVD-29. CONTINUATION OF TEMOZOLOMIDE CHEMOTHERAPY IN A GLIOBLASTOMA PATIENT AFTER RESOLUTION OF COVID-19 PNEUMONIA." Neuro-Oncology 22, Supplement_2 (2020): ii26—ii27. http://dx.doi.org/10.1093/neuonc/noaa215.110.

Full text

Abstract:

Abstract We present a case of a 33 year-old patient with glioblastoma (IDH wild type, MGMT unmethylated) who was diagnosed with COVID-19 pneumonia while undergoing chemotherapy. The patient did not have any medical comorbidities. He was clinically asymptomatic following surgery, completed concurrent phase of combined chemotherapy and radiation and was undergoing treatment with adjuvant temozolomide. He had radiographic improvement of the brain tumor (decreased size, contrast enhancement and T2 flair) after three cycles of adjuvant temozolomide. However, after cycle three the patient developed

APA, Harvard, Vancouver, ISO, and other styles

28

Thomas, Xavier, Ida Lobe, Emmanuel Raffoux, et al. "Intensive Consolidation with Clofarabine and Intermediate-Dose Cytarabine (CLARA) in Patients with High-Risk AML in First CR: The ALFA-0702 Pilot Study." Blood 112, no. 11 (2008): 1934. http://dx.doi.org/10.1182/blood.v112.11.1934.1934.

Full text

Abstract:

Abstract Introduction. One standard option for consolidation chemotherapy in younger patients with acute myeloid leukemia (AML) in first CR (CR1) is based on 3 to 4 repeated cycles of high-dose cytarabine (HDAC), according to the CALGB schedule (RJ. Mayer, NEJM 1994). Nevertheless, relapse incidence remains high, especially in those with high-risk AML features and no available donor for allogeneic stem cell transplantation (SCT). Combination of clofarabine with intermediate-dose cytarabine (CLARA) has been reported to induce promising response rate in high-risk AML patients (S. Faderl, Blood 2

APA, Harvard, Vancouver, ISO, and other styles

29

Kutny, Matthew A., Todd A. Alonzo, Robert B. Gerbing, et al. "Results of a Phase III Trial Including Arsenic Trioxide Consolidation for Pediatric Patients with Acute Promyelocytic Leukemia (APL): A Report from the Children's Oncology Group Study AAML0631." Blood 126, no. 23 (2015): 219. http://dx.doi.org/10.1182/blood.v126.23.219.219.

Full text

Abstract:

Abstract Results from cooperative group trials demonstrating the effectiveness of arsenic trioxide in the treatment of newly diagnosed APL have thus far been restricted to trials consisting of primarily adult patients. The Children's Oncology Group trial AAML0631 incorporated two cycles of arsenic trioxide (ATO) during consolidation with approximately 40% reduction in anthracycline dosing compared to the Italian AIDA0493 trial which has the largest cohort and best phase III results published for pediatric APL (Testi et al Blood 2005). Eligibility criteria included age ≥ 2 to < 22 years, de

APA, Harvard, Vancouver, ISO, and other styles

30

Ikarashi, Koyuki, Daisuke Sato, Kaho Iguchi, Yasuhiro Baba, and Koya Yamashiro. "Menstrual Cycle Modulates Motor Learning and Memory Consolidation in Humans." Brain Sciences 10, no. 10 (2020): 696. http://dx.doi.org/10.3390/brainsci10100696.

Full text

Abstract:

Numerous studies have noted that sex and/or menstrual phase influences cognitive performance (in particular, declarative memory), but the effects on motor learning (ML) and procedural memory/consolidation remain unclear. In order to test the hypothesis that ML differs across menstrual cycle phases, initial ML, overlearning, consolidation, and final performance were assessed in women in the follicular, preovulation and luteal phases. Primary motor cortex (M1) oscillations were assessed neuro-physiologically, and premenstrual syndrome and interoceptive awareness scores were assessed psychologica

APA, Harvard, Vancouver, ISO, and other styles

31

Benke, Stan, E. J. Bow, B. Schacter, et al. "Infectious Morbidity and Hospitalization Requirements of Patients with Acute Myeloid Leukemia Receiving Intensive Outpatient Consolidation." Blood 104, no. 11 (2004): 4524. http://dx.doi.org/10.1182/blood.v104.11.4524.4524.

Full text

Abstract:

Abstract Limited inpatient resources have focused interest upon the outpatient administration of intensive post-remission consolidation of acute myeloid leukemia (AML). Experience is limited in this regard (Blood 2002, 100:766a). In August 2001 a program of post-remission outpatient consolidation was instituted in our centre. A total of 68 cycles were administered to 35 patients with AML over 36 months. Standard prophylaxis included ciprofloxacillin and acyclovir. Our study was designed to look at infectious complications and requirement for hospitalization. Median age of patients was 54.5 yea

APA, Harvard, Vancouver, ISO, and other styles

32

Yeshurun, Moshe, Myriam Labopin, Didier Blaise, et al. "Impact of Postremission Consolidation Chemotherapy On Outcome After Reduced-Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) for AML in First Complete Remission (CR1): A Report From the Acute Leukemia Working Party of EBMT." Blood 120, no. 21 (2012): 3098. http://dx.doi.org/10.1182/blood.v120.21.3098.3098.

Full text

Abstract:

Abstract Abstract 3098 The role of consolidation therapy after successful remission induction is well established in the treatment paradigm of patients with AML in the non-transplant setting. Most contemporary treatment protocols for young AML patients not transplanted in CR1 include repetitive cycles of high-dose cytarabine. However, in the standard myeloablative allo-SCT setting, consolidation therapy prior to transplant did not prove to have a beneficial impact on overall survival (OS), leukemia free survival (LFS) or relapse incidence (RI) as shown in 2 previous studies from the IBMTR and

APA, Harvard, Vancouver, ISO, and other styles

33

Kolitz, Jonathan E., Stephen Anthony Strickland, Jorge E. Cortes, et al. "Efficacy by consolidation administration site: Subgroup analysis of a phase III study of CPX-351 versus 7+3 in older adults with newly diagnosed, high-risk acute myeloid leukemia (AML)." Journal of Clinical Oncology 35, no. 15_suppl (2017): 7036. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.7036.

Full text

Abstract:

7036 Background: The CPX-351 liposomal formulation delivers a synergistic 5:1 molar ratio of cytarabine (C) and daunorubicin (D) preferentially to leukemia cells. CPX-351 has demonstrated significantly improved overall survival (OS) versus 7+3 in a randomized, open-label, phase III study in patients (pts) aged 60-75 years with newly diagnosed, high-risk AML. In contrast to 7+3, which includes C continuous infusion, CPX-351 is administered as a 90-minute infusion and has the potential to be given in the outpatient setting. The current analysis of the phase III trial assessed the setting of cons

APA, Harvard, Vancouver, ISO, and other styles

34

David, Kevin A., Mitchell R. Smith, Izidore S. Lossos, et al. "A Phase II Trial of Combination Bortezomib (Velcade®) and Rituximab for Untreated “High Tumor Burden” Indolent Non-Hodgkin Lymphoma (NHL)." Blood 112, no. 11 (2008): 2004. http://dx.doi.org/10.1182/blood.v112.11.2004.2004.

Full text

Abstract:

Abstract Traditional therapy for patients with symptomatic and/or high-risk indolent NHL most commonly includes rituximab combined with multiagent cytotoxic chemotherapy. However some patients are not able to tolerate chemotherapy due to advanced age and/ or co-morbidities. Further, combination of novel, targeted agents (non-chemotherapeutic) have been infrequently tested in newly diagnosed indolent NHL patient populations. Overall response rate (ORR) with single-agent rituximab in prior data for untreated indolent NHL was 73% with a complete remission (CR) rate of 37% following maintenance th

APA, Harvard, Vancouver, ISO, and other styles

35

Ward, Richard, Vikas Gupta, Mark D. Minden, et al. "Feasibility of Outpatient Consolidation Chemotherapy and Toxicity in Elderly Patients with AML." Blood 114, no. 22 (2009): 1036. http://dx.doi.org/10.1182/blood.v114.22.1036.1036.

Full text

Abstract:

Abstract Abstract 1036 Poster Board I-58 Introduction: Consolidation chemotherapy is frequently administered on an outpatient basis in younger AML patients. However, the safety of this maneuver in older patients is unclear owing to increased co-morbidities and declines in performance status (PS) in these patients. Methods: 215 newly diagnosed AML patients aged >60 years were referred to Princess Margaret Hospital between 2002 and 2005. Of these, 108 received non-protocol treatments (32 non-intensive experimental therapy, 12 intensive chemotherapy on a study protocol, and 64 palliative thera

APA, Harvard, Vancouver, ISO, and other styles

36

Sonneveld, Pieter, Emilie Asselbergs, Sonja Zweegman, et al. "Carfilzomib Combined with Thalidomide and Dexamethasone (CTD) Is an Highly Effective Induction and Consolidation Treatment in Newly Diagnosed Patients with Multiple Myeloma (MM) Who Are Transplant Candidate." Blood 120, no. 21 (2012): 333. http://dx.doi.org/10.1182/blood.v120.21.333.333.

Full text

Abstract:

Abstract Abstract 333 Background: Combinations of a proteasome inhibitor (PI) with an Imid plus dexamethason such as VRD or VTD have shown significant activity in newly diagnosed Multiple Myeloma. The use of these regimens is hampered by toxicity such as polyneuropathy and costs. Carfilzomib is a second generation PI that has shown activity as single agent and in combinations. Introduction: This investigator sponsored, dose escalation phase 2 trial was designed to investigate carfilzomib (C) combined with thalidomide (T) and dexamethasone (D) (CTD) for induction and consolidation treatment in

APA, Harvard, Vancouver, ISO, and other styles

37

Deotare, Uday, Marwan Shaheen, Joseph M. Brandwein, et al. "Predictive Value of Molecular Remissions Post Consolidation Chemotherapy in Patients with Core Binding Factor (CBF) Acute Myeloid Leukemias – a Single Centre Analysis." Blood 124, no. 21 (2014): 3693. http://dx.doi.org/10.1182/blood.v124.21.3693.3693.

Full text

Abstract:

Abstract Background: Acute myeloid leukemia (AML) with t(8;21) or inv(16) is commonly referred to as core-binding factor AML (CBF-AML). Although this group represents a favorable cytogenetic AML subgroup, 30-40% of these patients nevertheless relapse after standard intensive chemotherapy. The incorporation of high-dose cytarabine for postremission therapy has substantially improved the outcome of CBF-AML patients, especially when administered as 2-4 repetitive cycles. Here we present retrospective data from a single centre, on this favourable AML subgroup. Methods: We analyzed retrospectively

APA, Harvard, Vancouver, ISO, and other styles

38

Valentini, Daniele, and Debapria Das. "Three Separate Instances of Cytarabine-Induced SIADH." Canadian Journal of General Internal Medicine 17, no. 3 (2022): 43–46. http://dx.doi.org/10.22374/cjgim.v17i3.608.

Full text

Abstract:

We present a case of cytarabine-induced syndrome of inappropriate secretion of antidiuretic hormone (SIADH), a rare manifestation and complication, which based on review of the medical literature was reported only in one prior case report. It involves a 74-year-old male with acute myeloid leukemia who developed asymptomatic hyponatremia during three cycles of consolidation chemotherapy with high-dose cytarabine (HiDAC). Urine studies were consistent with SIADH. Due to the rapid onset and timing throughout all three cycles, the SIADH was suspected to be secondary to cytarabine. Serum sodium qui

APA, Harvard, Vancouver, ISO, and other styles

39

Guo, Zhenghuai, Klaus Regenauer-Lieb, Phung Nhu Hao Vu, and Zhenliang Guan. "Characteristics of Elastoplastic Consolidation by Compaction and Its Effects on Coal Permeability." Energies 15, no. 20 (2022): 7647. http://dx.doi.org/10.3390/en15207647.

Full text

Abstract:

This paper presents a combined experimental–analytical investigation of coal strain development under fluctuating applied hydrostatic stress. The laboratory setup mimics the isotropic volumetric compaction of coal under burial–uplift cycles in the absence of tectonic stress. Special emphasis is placed on the corresponding permeability evolution of the coal strata. Our results show that the stress–strain path is exponential, approaching a linear relation in the logarithmic stress–strain space with the monotonic increase in stress. A similar behavior is found for the strain–permeability path in

APA, Harvard, Vancouver, ISO, and other styles

40

Ribera, Josep-Maria, Olga Garcia, Pau Montesinos, et al. "Comparison of Short-Term Outcomes Between CSTIBES02 and ALL Ph08 Trials for Young Patients with Philadephia Chromosome-Positive ALL (Ph+ALL) Differing In Imatinib Dose and Amount of Chemotherapy Before Stem Cell Transplantation." Blood 118, no. 21 (2011): 2582. http://dx.doi.org/10.1182/blood.v118.21.2582.2582.

Full text

Abstract:

Abstract Abstract 2582 Background and objectives. Concurrent imatinib and chemotherapy followed by allogeneic stem cell transplantation (SCT) is the most used treatment for young patients with Ph+ALL. However, the amount of chemotherapy before SCT is not well established. The Spanish PETHEMA Group conducted two consecutive protocols (CSTIBES02 -Haematologica 2010; 95: 87–95- and ALL Ph08) differing in the imatinib dose (400 mg/d vs. 600 mg/d) and the amount of chemotherapy (two consolidation cycles vs. one consolidation cycle) before SCT. The short –term outcomes are herein compared. Patients

APA, Harvard, Vancouver, ISO, and other styles

41

Tallman, M. S., F. R. Appelbaum, D. Amos, et al. "Evaluation of intensive postremission chemotherapy for adults with acute nonlymphocytic leukemia using high-dose cytosine arabinoside with L-asparaginase and amsacrine with etoposide." Journal of Clinical Oncology 5, no. 6 (1987): 918–26. http://dx.doi.org/10.1200/jco.1987.5.6.918.

Full text

Abstract:

In order to test the toxicity and efficacy of intensive postremission therapy with high-dose cytosine arabinoside with L-asparaginase and amsacrine with etoposide in adults with acute nonlymphocytic leukemia (ANL), 100 adults (ages 19 to 75) with previously untreated ANL were entered into a study using six sequential cycles of chemotherapy. Cycles 1 (induction), 3, and 5 included conventional doses of daunomycin, cytosine arabinoside, 6-thioguanine, vincristine (VCR), and prednisone. Cycle 2 was cytosine arabinoside 3 g/m2 intravenously (IV) every 12 hours for four doses, followed by L-asparag

APA, Harvard, Vancouver, ISO, and other styles

42

Peles, Shachar, Nicholas M. Fisher, Feng Gao, et al. "Once Weekly Bortezomib (Velcade) Preserves Bone Health by a Direct Effect on Osteoclast Function Independent of Its Effect on the Malignant Plasma Cells." Blood 106, no. 11 (2005): 3458. http://dx.doi.org/10.1182/blood.v106.11.3458.3458.

Full text

Abstract:

Abstract Bone resorption is increased in multiple myeloma (MM) due to increased osteoclast activity leading to osteoporosis and osteolytic bone lesions. Assays of urinary excretion of N-telopeptide (NTX), a highly specific marker of bone resorption, decrease by 20–70% following treatment with bisphosphonates. Receptor activator of NF-kB (RANK) ligand increases osteoclast mediated bone resorption in part through activation of nuclear factor kappa-B(NF-kB). Preclinical studies have shown bortezomib to decrease osteoclast function through inhibition of NF-kB. However, no clinical data exists on t

APA, Harvard, Vancouver, ISO, and other styles

43

Ferreira, Marina de Souza, Fernando Saboya Albuquerque Junior, Sérgio Tibana, and Ricardo Garske Borges. "Experimental analysis of improved bearing capacity in offshore foundations due to thermal consolidation." Soils and Rocks 45, no. 1 (2022): 1–11. http://dx.doi.org/10.28927/sr.2022.078021.

Full text

Abstract:

The anchoring of floating platforms is one of many processes in the oil industry that requires innovative strategies. In this respect, there is interest in developing techniques that improve the shear strength of soft soils in order to increase the bearing capacity of offshore foundations anchored in these soils. Normally consolidated clay soil is known to undergo thermal consolidation when submitted to temperature cycles. The present study aimed to assess the impact of a temperature cycle on soft kaolin clay using a reduced-scale physical model submitted to heating at maximum temperatures of

APA, Harvard, Vancouver, ISO, and other styles

44

Jacoby, Meagan A., Michael Martin, Teresa Reineck, et al. "Phase I Study of Oral Clofarabine Consolidation in Adults Aged 60 and Older with Acute Myeloid Leukemia,." Blood 118, no. 21 (2011): 3633. http://dx.doi.org/10.1182/blood.v118.21.3633.3633.

Full text

Abstract:

Abstract Abstract 3633 Background: Less than 16% of adults aged 60 and older diagnosed with acute myeloid leukemia (AML) will remain disease free after cytarabine consolidation. Clofarabine (clo) is a next generation nucleoside analogue whose IV formulation has shown considerable activity in older patients with AML considered unlikely to benefit from conventional therapy. This phase I trial is the first study of an oral formulation of clo for consolidation in patients >= 60 with AML who achieve a remission with cytotoxic induction regimens. Methods: The primary objective was to determine th

APA, Harvard, Vancouver, ISO, and other styles

45

Perkins, Steven W., and Morten Sjursen. "Effect of cold temperatures on properties of unfrozen Troll clay." Canadian Geotechnical Journal 46, no. 12 (2009): 1473–81. http://dx.doi.org/10.1139/t09-041.

Full text

Abstract:

Oedometer and triaxial experiments have been performed on North Sea Troll clay previously warmed to room temperature and tested at both room temperature and 0 °C to assess the effect of cold temperature on undrained strength and consolidation properties. In general, both the undrained strength and preconsolidation pressure increase as the temperature decreases. Many subsea areas of development in extreme northern or southern latitudes experience seafloor temperatures continuously around 0 °C. These results suggest that conventional laboratory testing at room temperature of samples from these a

APA, Harvard, Vancouver, ISO, and other styles

46

Zimek, Martina, Andreas Schober, Claudia Mair, Rupert J. Baumgartner, Tobias Stern, and Manfred Füllsack. "The Third Wave of LCA as the “Decade of Consolidation”." Sustainability 11, no. 12 (2019): 3283. http://dx.doi.org/10.3390/su11123283.

Full text

Abstract:

Several authors have pointed out the importance of systems thinking, and have considered both environmental and social aspects (holistic perspective) of sustainability assessment in the past. Sustainability assessment tools which integrate different aspects (e.g., environmental/social aspects) in order to identify negative impacts have already been developed. Common tools used to assess environmental, social, or economic impacts include the life cycle assessment (LCA), social life cycle assessment (S-LCA), life cycle costing (LCC) and life cycle sustainability assessment (LCSA) approaches. The

APA, Harvard, Vancouver, ISO, and other styles

47

Schaich, Markus, Stefani Parmentier, Michael Kramer, et al. "High-Dose Cytarabine Consolidation With or Without Additional Amsacrine and Mitoxantrone in Acute Myeloid Leukemia: Results of the Prospective Randomized AML2003 Trial." Journal of Clinical Oncology 31, no. 17 (2013): 2094–102. http://dx.doi.org/10.1200/jco.2012.46.4743.

Full text

Abstract:

Purpose To assess the treatment outcome benefit of multiagent consolidation in young adults with acute myeloid leukemia (AML) in a prospective, randomized, multicenter trial. Patients and Methods Between December 2003 and November 2009, 1,179 patients (median age, 48 years; range, 16 to 60 years) with untreated AML were randomly assigned at diagnosis to receive either standard high-dose cytarabine consolidation with three cycles of 18 g/m2 (3× HD-AraC) or multiagent consolidation with two cycles of mitoxantrone (30 mg/m2) plus cytarabine (12 g/m2) and one cycle of amsacrine (500 mg/m2) plus cy

APA, Harvard, Vancouver, ISO, and other styles

48

Claxton, David F., Thomas J. Myers, Harry P. Erba, et al. "Outpatient Treatment with Clofarabine in a Phase II Study of Older Adult Patients with Previously Untreated Acute Myelogenous Leukemia (AML)." Blood 114, no. 22 (2009): 4162. http://dx.doi.org/10.1182/blood.v114.22.4162.4162.

Full text

Abstract:

Abstract Abstract 4162 Introduction The CLASSIC II trial previously reported an overall remission rate of 46% (38% complete remission [CR] and 8% CR with incomplete platelet recovery [CRp]), median duration of remission 56 weeks, median disease-free survival 37 weeks, median overall survival 41 weeks, and 30- and 60-day mortality rates 10% and 16%, respectively (JCO 2009; 27:371s, A.7062). Among the patients achieving remission, 75% achieved a CR or CRp after the first induction cycle and 25% after the re-induction cycle. This trial allowed physicians the discretion to treat patients with inpa

APA, Harvard, Vancouver, ISO, and other styles

49

Roussel, Murielle, Gaëlle Dörr, Willy Vaillant, Anne Huynh, and Michel Attal. "Consolidation with Bortezomib, Thalidomide and Dexamethasone After High Dose Therapy Is Feasible, Safe and Effective In De Novo Multiple Myeloma Patients Who Already Received New Drugs Containing-Induction Regimen." Blood 116, no. 21 (2010): 3041. http://dx.doi.org/10.1182/blood.v116.21.3041.3041.

Full text

Abstract:

Abstract Abstract 3041 High dose therapy (HDT) with autologous stem cell transplantation (ASCT) is a standard treatment option for frontline myeloma patients (pts). However, after a single or a double transplantation, almost all pts ultimately relapse. Thus, new strategies are required to control the residual disease after HDT. Consolidation therapy, given early after HDT, could enhance the depth of response and further improve progression free survival (PFS) and overall survival (OS). The IFM (Intergroupe Francophone du Myélome) previously reported that either Thalidomide or Lenalidomide, ad

APA, Harvard, Vancouver, ISO, and other styles

50

Dong, Yun, and Bao Tian Wang. "Test Study on Mechanical Properties of the Lime Stabilized Expansive Soil under Wet and Dry Cycle." Applied Mechanics and Materials 174-177 (May 2012): 166–70. http://dx.doi.org/10.4028/www.scientific.net/amm.174-177.166.

Full text

Abstract:

Lime Stabilized expansive soil is often used as filler in road subgrade, although many scholars have done a lot of research, the mechanical properties under wet and dry cycle role remains unclear. The paper Carried out direct shear test, consolidation test and CBR test on the lime stabilized expansive soil after the different times of wet and dry cycle. The test results show: The strength of soil will decrease, especially in previous cycle, and the trends can be expressed with logarithmic model; the deformation index (compression coefficient) of soil will increase, especially in previous cycle

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!